Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

62.27
-0.7800-1.24%
Pre-market: 62.430.1585+0.25%04:33 EDT
Volume:6.24M
Turnover:392.59M
Market Cap:11.24B
PE:-43.43
High:65.79
Open:65.64
Low:61.22
Close:63.05
52wk High:104.32
52wk Low:40.77
Shares:180.43M
Float Shares:115.00M
Volume Ratio:0.85
T/O Rate:5.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.55%
PB:25.25
PE(LYR):-44.16

Loading ...

Tempus Announces Strategic Collaboration With Daiichi Sankyo To Advance Ai-Driven Biomarker Discovery And Clinical Differentiation Across An Adc Clinical Program

Reuters
·
Mar 25

Tempus AI Shares up 2% Premarket After Partnering With Daiichi Sankyo for Cancer Drug

THOMSON REUTERS
·
Mar 25

BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug

Reuters
·
Mar 25

AI Software Stocks Fall. Figma Down About 6%; Palantir Down 5%; Workday, SoundHound AI, Salesforce, AppLovin, Snowflake Down over 4%

Tiger Newspress
·
Mar 24

Did Tempus AI's (TEM) Pediatric AML Registry Push into Patient Apps Just Shift Its Investment Narrative?

Simply Wall St.
·
Mar 17

Tempus AI, Blood Cancer United announce strategic collaboration

TIPRANKS
·
Mar 17

BRIEF-Tempus And Blood Cancer United® Announce Collaboration To Develop One Of The Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Reuters
·
Mar 17

Tempus and Blood Cancer United® Announce Collaboration to Develop One of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

THOMSON REUTERS
·
Mar 17

Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform

Simply Wall St.
·
Mar 13

Why Tempus AI Stock Is Up Wednesday?

Benzinga_recent_news
·
Mar 11

Tempus AI study finds 12% of community oncology patients gain actionable results from advanced genomic profiling features

Reuters
·
Mar 11

Tempus AI Price Target Maintained With a $75.00/Share by Needham

Dow Jones
·
Mar 11

Tempus AI: Underappreciated Oncology Platform and Data Business Poised for Reimbursement Upside and AI-Driven Growth

TIPRANKS
·
Mar 11

Tempus AI Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 10

Tempus AI price target raised to $95 from $89 at H.C. Wainwright

TIPRANKS
·
Mar 10